Alto Neuroscience ANRO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$74.31M-17.5% | -$63.24M-1.6% | -$62.26M+4.0% | -$64.86M-2.7% | -$63.18M-2.9% | ||
| $641K+2.1% | $628K-2.0% | $641K0.0% | $641K0.0% | $641K+13.1% | ||
| $8.96M+10.6% | $8.11M+4.9% | $7.73M+2.5% | $7.54M+1.6% | $7.42M-2.8% | ||
| -$62.3M-20.4% | -$51.77M+2.8% | -$53.27M+3.3% | -$55.08M-3.9% | -$53M-11.8% | ||
| —— | —— | —— | —— | $1.88M-9.6% | ||
| —— | —— | —— | —— | -$1.88M+9.6% | ||
| —— | —— | —— | —— | $10.21M— | ||
| $165.89M+176% | $60.08M+504% | $9.94M-10.5% | $11.11M+5.8% | $10.49M-92.3% | ||
| $103.01M+1,148% | $8.26M— | —— | —— | —— | ||
| -$62.86M-21.4% | -$51.79M+3.7% | -$53.8M+5.0% | -$56.62M-3.2% | -$54.87M-10.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alto Neuroscience generate?
- Alto Neuroscience (ANRO) generated -$62.3M in operating cash flow over the trailing twelve months.
- What is Alto Neuroscience's free cash flow?
- After $2.1M of capital expenditures, Alto Neuroscience's free cash flow was -$62.9M over the trailing twelve months, down 14.6% year over year.
- Where does Alto Neuroscience's cash flow data come from?
- Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.